Olema Pharmaceuticals (OLMA) Accumulated Expenses (2020 - 2026)

Olema Pharmaceuticals (OLMA) has reported Accumulated Expenses for 7 consecutive years, with $2.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Accumulated Expenses rose 202.06% year-over-year to $2.2 million; the TTM figure through Mar 2026 stood at $2.2 million (up 202.06% YoY), while the FY2025 annual figure was $8.3 million, up 45.79% from the prior year.
• Accumulated Expenses declined to $2.2 million in Q1 2026 per OLMA's latest filing, from $8.3 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $12.8 million in Q3 2023 and bottomed at $184000.0 in Q2 2022.
• Historically, Accumulated Expenses has averaged $2.7 million across 5 years, with a median of $729000.0 in 2025.
• Annual changes were most pronounced in 2022 — Accumulated Expenses tumbled 92.11% — and 2023, when it soared 3061.33%.
• Olema Pharmaceuticals' Accumulated Expenses stood at $296000.0 in 2022, then surged by 1746.28% to $5.5 million in 2023, then increased by 3.59% to $5.7 million in 2024, then surged by 45.79% to $8.3 million in 2025, then sank by 73.32% to $2.2 million in 2026.
• Business Quant data shows OLMA's Accumulated Expenses at $2.2 million in Q1 2026, $8.3 million in Q4 2025, and $406000.0 in Q3 2025.